Biosimilars in Emerging Markets

Publication date:
March 2013
Adding to cart… The item has been added

There are few areas of the pharmaceutical market more hotly debated than biosimilars yet the pathway to developing a viable global product marketplace is not clear. Biosimilar interest is being driven by the potential offered by a range of high-value brands which will be subject to patent challenges in the next 5-10 years such as Roche’s Herceptin and Avastin.

The fundamentals of biosimilars in emerging markets are sound: high unmet clinical need in large and expanding populations, growing GDP and health spending, increasing patient expectation and often amenable regulatory regimes all provide a fertile environment for biosimilar products. Many biosimilar companies in emerging markets are developing networks and alliances outside of the US and Europe which is providing valuable revenue and knowledge of international trade. Are we seeing a 2-speed biosimilars sector in which emerging markets and companies are taking a lead?

Key Benefits

Understanding this complex market requires a detailed analysis of the trends which are shaping its development. Biosimilars in Emerging Markets is a 2-volume report which provides both a comprehensive overview of the biosimilars sector and highly-detailed expert analysis of the issues that are affecting developments on the ground in a range of emerging markets including Korea, India, China, Brazil, Russia and Turkey.

VOLUME 1: Putting emerging markets and companies into global context

This detailed volume succinctly reviews the biosimilars sector and will ensure you have a complete working brief of the current state of emerging markets in their international context. It provides a review of regulations covering biosimilars, identifies sales and patent expiry of leading biological brands and looks at market value and biosimilar pricing. There are country-by-country appraisals of leading emerging economies which examine the biosimilar operating environment along with company profiles of 23 local biosimilar developers with pipeline analysis for leading organisations.

VOLUME 2: Drilling down into emerging markets: local industry experts share their insights

What trends are driving biosimilars in emerging markets? Many countries have the need for biosimilars but do not have the development or manufacturing capacity to produce biosimilars for their own population. At the other end of the scale, a good deal of government interest and incentive for private companies has established the necessary framework for national/regional supply with long term ambitions for US/Europe. Even so, biosimilar companies may face challenges even with their own markets such as patient and clinical concerns over safety and quality. Volume 2 brings together highly-detailed market analysis with contributions from local industry experts whose clear insights provide a real world perspective of opportunities and challenges which must be overcome now and in the future


Biosimilars in Emerging Markets answers key questions including:

  • Which emerging market companies have biosimilar versions of Roche’s Herceptin in development?
  • With which companies has Korean biosimilar company Celltrion struck alliances?
  • What role Korean electronics giants Samsung and LG are playing in the biosimilars area?
  • How Roche has responded to falling sales of MabThera as it comes under pressure from Dr Reddy’s Reditux biosimilar in India?
  • What the data requirements are for biosimilar applications in Latin America and how they vary between countries?
  • How the Brazilian government is incentivising biosimilar developers?
  • How Turkey can play an influential role in the markets for biosimilars in the Middle East?
  • Which Russian companies are building new bio-manufacturing plants?

Selected Quotes from Volume 2

From Brazil...
“Most companies do not think beyond their local market. With 60 plus companies going after the same biosimilar portfolio, companies looking globally may have a strategic advantage and emerge as a winner,” H Fai Poon, R&D Director, Hisun Pharma China

From India...
“In addition to our success in India, Biocon supplies 60% of the world’s biosimilar insulin to emerging markets like Mexico, Brazil, the Middle East, North Africa and many parts of Southeast Asia,” Kiran Mazumdar Shaw, CEO and Chairman of Biocon, Biosimilar Manufacturer

From Russia...
“We don’t consider European or US markets as our priority in the long term. We are focused in the short term on markets of Russia with Southeast Asia and Latin America as mid-term goals,” Roman Ivanov, VP of R&D Biocad, Biosimilar Manufacturer

On South Korea...
“The public and physician perception of biosimilars is critical for their acceptance in the Korean market. We believe that there needs to be huge investments in educational and marketing activities in both pre-and post-launch of these products,” Paul Coleman, CEO, Hanwha Biologics